Efficacy of nimotuzumab according to inflammatory indices in patients with advanced non-small cell lung cancer
Keywords:
antibodies, monoclonal, carcinoma, non-small-cell lung, drug therapy, efficacy, lung neoplasms, therapeutics.Abstract
Introduction: The response to therapies in advanced lung cancer could be related to certain prognostic factors such as inflammatory indices.
Objective: To evaluate the efficacy of the humanized monoclonal antibody nimotuzumab in patients with advanced non-small cell lung cancer according to inflammatory indices.
Method: A retrospective longitudinal evaluation study was carried out in a universe of 498 patients older than 18 years, with a cytohistological diagnosis of non-small cell lung cancer, in advanced stages, after the first line of oncological therapy, including in multicenter clinical trials promoted by the Center for Molecular Immunology from 2002 to 2018. Descriptive statistics were applied, the x-tile 3.6.1 software was used for the Kaplan Meier test, significant differences were considered when p< 0,05.
Results: In the patients analyzed, nimotuzumab showed therapeutic benefit in the group of patients who did not progress to the first line of treatment with chemotherapy or chemoradiotherapy, when they had a lower neutrophil-lymphocyte index (p= 0,017 and p= 0,027) and a lower platelet-lymphocyte index (p= 0,030 and p= 0,009).
Conclusion: Selecting a patient with a lower inflammatory index benefits the efficacy of treatment with the humanized mAb nimotuzumab in advanced non-small cell lung cancer, which becomes a predictive tool for response to treatment.
Downloads
Download data is not yet available.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Jemal A. Global Cancer Statistics 2020: GLOBOCAN, Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):191-280. DOI: 10.3322/caac.21660
2. Ministerio de Salud Pública. Dirección de Registro Médicos y Estadísticas de Salud. Anuario estadístico de salud 2019. La Habana: MINSAP; 2020. [acceso: 19/08/2022]. Disponible en: https://salud.msp.gob.cu/wp-content/Anuario/anuario_2019_edici%C3%B3n_2020.pdf
3. Murphy SE, Park SL, Balbo S, Haiman CA, Hatsukami DK. Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers. NPJ precision oncology. 2018; 2(1):1-10. DOI:10.1038/s41698-018-0057-y
4. Bade BC, Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in Chest Medicine. 2020;41(1):1-24. DOI:10.1016/j.ccm.2019.10.001
5. Sánchez Ríos CP, Rumbo NU, Báez SR, Rivera Rosales RM, Luna Rivero C. Perfil mutacional de EGFR en adenocarcinoma pulmonar en pacientes fumadores y no fumadores. Neumol. cir. torax. 2018 [acceso: 05/09/2022]; 77(2):137-44. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0028-37462018000200137&lng=es
6. Arrieta O, Cardona AF, Zatarain Barron ZL, Rolfo C, Ordoñez C. Historia del cáncer de pulmón: desde Doll y Hill hasta las terapias de precisión. Revista Medicina. 2021; [acceso: 18/08/2022]; 43(1):107-39. Disponible en: https://www.revistamedicina.net/index.php/Medicina/article/view/1589/2038
7. Remon J. La revolución de la inmunoterapia: Inhibidores de punto de control inmune para el cáncer de pulmón de células no pequeñas. Revista Medicina. 2021 [acceso: 18/08/2022]; 43(1):176-88. Disponible en: https://www.revistamedicina.net/index.php/Medicina/article/view/1593/2045
8. CECMED. Resumen de las características del producto. La Habana: CECMED; 2019. [acceso: 19/08/2022]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cimaher.pdf
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Pennsylvania: NCCN; 2020. [acceso: 26/06/2021]. Disponible en: https://www2.trikobe.org/nccn/guideline/lung/english/non_small.pdf
10. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer. 2018; 9(18): 3295. DOI: 10.7150/jca.25691
11. Howard R, Peter A, Kanetsky P, Kathleen M, Egan H. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Scientific Reports. 2019; 9:19673. DOI: 10.1038/s41598-019-56218-z
12. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713
13. CECMED. Resolución Ministerial No.165/2000. Directrices sobre Buenas Prácticas Clínicas en Cuba. La Habana: CECMED; 2021. [acceso: 12/12/2021].Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/ambitor/ambreg-18.pdf
14. Carballo Torres D, Nenínger Vinageras E, Soriano García JL, Saavedra Hernández D, Viada González C. Supervivencia en pacientes con cáncer pulmonar no microcítico avanzado en mantenimiento con CIMAvax-EGF® o Nimotuzumab. Rev Cub Oncol. 2021 [acceso: 26/12/2022]; 19(1):112. Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/112
15. Alarcón ML, Brugés R, Carvajal C, Vallejo C, Beltrán R. Características de los pacientes con cáncer de pulmón de célula no pequeña en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2021; 25(2):103-9. DOI: 10.35509/01239015.706
16. Guo W, Cai S, Zhang F. Systemic immuneinflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac Cancer. 2019; 10(4): 761-8. DOI: 10.1111/1759-7714.12995
17. Yucel S, Bilgin B. The prognostic values of systemic immune inflammation index and derived neutrophillymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer. J Oncol Pharm Practice. 2020; 27(1):71-77. DOI: 10.1177/1078155220913106
18. Bilgin B, Sendur MAN, Hizal M. Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization. J Cancer Res Ther. 2019; 15(1):54-60. DOI:10.4103/jcrt.JCRT_624_17
19. Russo A, Franchina T, Ricciardi GRR. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel. J Cell Physio. 2018; 233(10): 6337-43. DOI: 10.1002/jcp.26609
20. Reyes Espinosa L, Crombet Ramos T, Lage Dávila A, Viada González CE. Inflammation Indexes Pretreatment Associated with Overall Survival and the Response to Nimotuzumab in Patients with Head and Neck Cancer Newly Diagnosed. Head Neck Cancer Res. 2021 [acceso: 01/12/2022]; 6(5):1-7. Disponible en: https://head-and-neck-cancer-research.imedpub.com/inflammation-indexes-pretreatment-associated-with-overall-survival-and-the-response-to-nimotuzumab-in-patients-with-head-and-neck.php?aid=40524
21. Zhang Y, Feng YC, Zhu HG. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs. Medicine (Baltimore). 2018; 97(30):11648. DOI: 10.1097/MD0000000000011648
22. Sebnem Y, Burak B. The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer. J Oncol Pharm Practice. 2021; 27(1):71-77. DOI:10.1177/1078155220913106
23. Zhang Y, Chen B, Wang L. Systemic immuneinflammation index is a promising noninvasive marker to predict survival of lung cancer: a meta-analysis. Medicine (Baltimore). 2019; 98(3):13788. DOI: 10.1097/MD0000000000013788
24. Deng C, Zhang N, Wang Y. High systemic immuneinflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Medicine (Baltimore). 2019; 98(33):16875. DOI: 10.1097/MD0000000000016875
25. Dennehy C, McMahon E, Power DG. Clinical haematological biomarkers: derived neutrophil-tolymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) and their relationship to survival outcomes in non-small cell lung cancer (NSCLC) treated with immunotherapy: a multicenter review. J Clin Oncol. 2019; 37(15):20704. DOI: 10.1200/JCO.2019.37.15_suppl.e2
2. Ministerio de Salud Pública. Dirección de Registro Médicos y Estadísticas de Salud. Anuario estadístico de salud 2019. La Habana: MINSAP; 2020. [acceso: 19/08/2022]. Disponible en: https://salud.msp.gob.cu/wp-content/Anuario/anuario_2019_edici%C3%B3n_2020.pdf
3. Murphy SE, Park SL, Balbo S, Haiman CA, Hatsukami DK. Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers. NPJ precision oncology. 2018; 2(1):1-10. DOI:10.1038/s41698-018-0057-y
4. Bade BC, Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in Chest Medicine. 2020;41(1):1-24. DOI:10.1016/j.ccm.2019.10.001
5. Sánchez Ríos CP, Rumbo NU, Báez SR, Rivera Rosales RM, Luna Rivero C. Perfil mutacional de EGFR en adenocarcinoma pulmonar en pacientes fumadores y no fumadores. Neumol. cir. torax. 2018 [acceso: 05/09/2022]; 77(2):137-44. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0028-37462018000200137&lng=es
6. Arrieta O, Cardona AF, Zatarain Barron ZL, Rolfo C, Ordoñez C. Historia del cáncer de pulmón: desde Doll y Hill hasta las terapias de precisión. Revista Medicina. 2021; [acceso: 18/08/2022]; 43(1):107-39. Disponible en: https://www.revistamedicina.net/index.php/Medicina/article/view/1589/2038
7. Remon J. La revolución de la inmunoterapia: Inhibidores de punto de control inmune para el cáncer de pulmón de células no pequeñas. Revista Medicina. 2021 [acceso: 18/08/2022]; 43(1):176-88. Disponible en: https://www.revistamedicina.net/index.php/Medicina/article/view/1593/2045
8. CECMED. Resumen de las características del producto. La Habana: CECMED; 2019. [acceso: 19/08/2022]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cimaher.pdf
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Pennsylvania: NCCN; 2020. [acceso: 26/06/2021]. Disponible en: https://www2.trikobe.org/nccn/guideline/lung/english/non_small.pdf
10. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer. 2018; 9(18): 3295. DOI: 10.7150/jca.25691
11. Howard R, Peter A, Kanetsky P, Kathleen M, Egan H. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Scientific Reports. 2019; 9:19673. DOI: 10.1038/s41598-019-56218-z
12. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713
13. CECMED. Resolución Ministerial No.165/2000. Directrices sobre Buenas Prácticas Clínicas en Cuba. La Habana: CECMED; 2021. [acceso: 12/12/2021].Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/ambitor/ambreg-18.pdf
14. Carballo Torres D, Nenínger Vinageras E, Soriano García JL, Saavedra Hernández D, Viada González C. Supervivencia en pacientes con cáncer pulmonar no microcítico avanzado en mantenimiento con CIMAvax-EGF® o Nimotuzumab. Rev Cub Oncol. 2021 [acceso: 26/12/2022]; 19(1):112. Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/112
15. Alarcón ML, Brugés R, Carvajal C, Vallejo C, Beltrán R. Características de los pacientes con cáncer de pulmón de célula no pequeña en el Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2021; 25(2):103-9. DOI: 10.35509/01239015.706
16. Guo W, Cai S, Zhang F. Systemic immuneinflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac Cancer. 2019; 10(4): 761-8. DOI: 10.1111/1759-7714.12995
17. Yucel S, Bilgin B. The prognostic values of systemic immune inflammation index and derived neutrophillymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer. J Oncol Pharm Practice. 2020; 27(1):71-77. DOI: 10.1177/1078155220913106
18. Bilgin B, Sendur MAN, Hizal M. Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization. J Cancer Res Ther. 2019; 15(1):54-60. DOI:10.4103/jcrt.JCRT_624_17
19. Russo A, Franchina T, Ricciardi GRR. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel. J Cell Physio. 2018; 233(10): 6337-43. DOI: 10.1002/jcp.26609
20. Reyes Espinosa L, Crombet Ramos T, Lage Dávila A, Viada González CE. Inflammation Indexes Pretreatment Associated with Overall Survival and the Response to Nimotuzumab in Patients with Head and Neck Cancer Newly Diagnosed. Head Neck Cancer Res. 2021 [acceso: 01/12/2022]; 6(5):1-7. Disponible en: https://head-and-neck-cancer-research.imedpub.com/inflammation-indexes-pretreatment-associated-with-overall-survival-and-the-response-to-nimotuzumab-in-patients-with-head-and-neck.php?aid=40524
21. Zhang Y, Feng YC, Zhu HG. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs. Medicine (Baltimore). 2018; 97(30):11648. DOI: 10.1097/MD0000000000011648
22. Sebnem Y, Burak B. The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer. J Oncol Pharm Practice. 2021; 27(1):71-77. DOI:10.1177/1078155220913106
23. Zhang Y, Chen B, Wang L. Systemic immuneinflammation index is a promising noninvasive marker to predict survival of lung cancer: a meta-analysis. Medicine (Baltimore). 2019; 98(3):13788. DOI: 10.1097/MD0000000000013788
24. Deng C, Zhang N, Wang Y. High systemic immuneinflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Medicine (Baltimore). 2019; 98(33):16875. DOI: 10.1097/MD0000000000016875
25. Dennehy C, McMahon E, Power DG. Clinical haematological biomarkers: derived neutrophil-tolymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) and their relationship to survival outcomes in non-small cell lung cancer (NSCLC) treated with immunotherapy: a multicenter review. J Clin Oncol. 2019; 37(15):20704. DOI: 10.1200/JCO.2019.37.15_suppl.e2
Published
2023-09-07
How to Cite
1.
Camacho Sosa K, Ramos Suzarte M, Viada González CE, Nenínger Vinageras E, Santiesteban Álvarez ER, Hernández Pérez M, et al. Efficacy of nimotuzumab according to inflammatory indices in patients with advanced non-small cell lung cancer. Rev Cubana Med Milit [Internet]. 2023 Sep. 7 [cited 2025 Apr. 3];52(3):e02303004. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/3004
Issue
Section
Research Article
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
